3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients

I. R. N. Verly, A. B. P. van Kuilenburg, N. G. G. M. Abeling, S. M. I. Goorden, M. Fiocco, F. M. Vaz, M. M. van Noesel, C. M. Zwaan, G. J. L. Kaspers, J. H. M. Merks, H. N. Caron, G. A. M. Tytgat

Research output: Contribution to journalArticleAcademicpeer-review

LanguageEnglish
Pages102-110
JournalEuropean Journal of Cancer
Volume90
DOIs
StatePublished - Feb 2018

Cite this

Verly, I. R. N., van Kuilenburg, A. B. P., Abeling, N. G. G. M., Goorden, S. M. I., Fiocco, M., Vaz, F. M., ... Tytgat, G. A. M. (2018). 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients. European Journal of Cancer, 90, 102-110. DOI: 10.1016/j.ejca.2017.11.025
Verly, I. R. N. ; van Kuilenburg, A. B. P. ; Abeling, N. G. G. M. ; Goorden, S. M. I. ; Fiocco, M. ; Vaz, F. M. ; van Noesel, M. M. ; Zwaan, C. M. ; Kaspers, G. J. L. ; Merks, J. H. M. ; Caron, H. N. ; Tytgat, G. A. M./ 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients. In: European Journal of Cancer. 2018 ; Vol. 90. pp. 102-110
@article{02fb7c98db8b4bd6b00597b1a4bab376,
title = "3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients",
author = "Verly, {I. R. N.} and {van Kuilenburg}, {A. B. P.} and Abeling, {N. G. G. M.} and Goorden, {S. M. I.} and M. Fiocco and Vaz, {F. M.} and {van Noesel}, {M. M.} and Zwaan, {C. M.} and Kaspers, {G. J. L.} and Merks, {J. H. M.} and Caron, {H. N.} and Tytgat, {G. A. M.}",
year = "2018",
month = "2",
doi = "10.1016/j.ejca.2017.11.025",
language = "English",
volume = "90",
pages = "102--110",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Pergamon",

}

Verly, IRN, van Kuilenburg, ABP, Abeling, NGGM, Goorden, SMI, Fiocco, M, Vaz, FM, van Noesel, MM, Zwaan, CM, Kaspers, GJL, Merks, JHM, Caron, HN & Tytgat, GAM 2018, '3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients' European Journal of Cancer, vol. 90, pp. 102-110. DOI: 10.1016/j.ejca.2017.11.025

3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients. / Verly, I. R. N.; van Kuilenburg, A. B. P.; Abeling, N. G. G. M.; Goorden, S. M. I.; Fiocco, M.; Vaz, F. M.; van Noesel, M. M.; Zwaan, C. M.; Kaspers, G. J. L.; Merks, J. H. M.; Caron, H. N.; Tytgat, G. A. M.

In: European Journal of Cancer, Vol. 90, 02.2018, p. 102-110.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients

AU - Verly,I. R. N.

AU - van Kuilenburg,A. B. P.

AU - Abeling,N. G. G. M.

AU - Goorden,S. M. I.

AU - Fiocco,M.

AU - Vaz,F. M.

AU - van Noesel,M. M.

AU - Zwaan,C. M.

AU - Kaspers,G. J. L.

AU - Merks,J. H. M.

AU - Caron,H. N.

AU - Tytgat,G. A. M.

PY - 2018/2

Y1 - 2018/2

U2 - 10.1016/j.ejca.2017.11.025

DO - 10.1016/j.ejca.2017.11.025

M3 - Article

VL - 90

SP - 102

EP - 110

JO - European Journal of Cancer

T2 - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -